ALBI Grade (Liver)ASTCT Grading ATA Thyroid Risk BCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPI CML ELTS Score CNS-IPI CTCAE v5.0 Calvert Formula DIPSS-Plus (Myelofibrosis)Deauville Score EAU NMIBC Risk ECOG Performance Status ELN 2022 Risk (AML)ELN CML Milestones FIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2 Fleischner 2017 Guidelines Fong Clinical Risk Score HCT-CI (Sorror Score)HPV/p16 Oropharynx IGCCCG Risk (Testicular)IMDC (Heng) Criteria IMWG Myeloma Frailty IPSS-M (Molecular MDS)ISUP Grade Groups Karnofsky Status (KPS)Khorana Score Lugano Classification Lung-RADS v2022 MIPI-b (Biological)MRD Assessment Framework MSI/MMR Interpretation Mayo 20/2/20 (SMM)NCCN Prostate Risk NCCN-IPI (DLBCL)NSCLC GPA Oncotype DX Recurrence Opioid Equianalgesic PD-L1 TPS Interpretation PERCIST 2.0 PREDICT v3.0 Platinum-Free Interval R2-ISS (Revised 2)RANO 2.0 RCB (Residual Cancer Burden)RECIST 1.1 ROMA Score SAVER Score SINS Score SLiM-CRAB Criteria Sedlis/Peters Criteria TNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AML Z0011 Eligibility iRECIST iwCLL 2018 Response mRECIST (HCC)mRENAL Score mrTRG (Rectal MRI)

Recent Journal Updates

Alzheimers & DementiaJun 8, 2026

Early microglial response to amyloid plaques drives sleep loss in Alzheimer's disease

Clinical Context

We think this might be relevant to the clinical guidance for ELN CML Response Milestones.

DiabetologiaJun 8, 2026

Genetics of MASLD: a diabetes perspective

Clinical Context

We think this might be relevant to the clinical guidance for ELN CML Response Milestones.

WHO NewsJun 5, 2026

Africa CDC and WHO launch joint continental Ebola response plan

Clinical Context

We think this might be relevant to the clinical guidance for ELN CML Response Milestones.

ELN CML Milestones

ELN CMLMolecular Milestone Assessment

TKI Response Metrics

Time on Therapy

BCR-ABL1 Level% (IS)

Awaiting Molecular PCR

Enter the molecular response to see if the patient is hitting the ELN targets.

Targets (Optimal)

3 Months: <= 10%
6 Months: <= 1%
12 Months: <= 0.1% (MMR)

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Monitoring patients with CML in Chronic Phase on any TKI (Imatinib, Dasatinib, etc.).

Dictating when to switch TKIs or perform BCR-ABL1 kinase domain mutation analysis.

Requires quantitative RT-PCR for BCR-ABL1 transcripts expressed on the International Scale (IS).

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the CML ELTS Score, Who Icc 2022 Aml or the CTCAE v5.0 to formulate a comprehensive care plan.

Last Comprehensive Review: 2026